Compare · MCRB vs STOK
MCRB vs STOK
Side-by-side comparison of Seres Therapeutics Inc. (MCRB) and Stoke Therapeutics Inc. (STOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCRB and STOK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- STOK is the larger of the two at $1.59B, about 62.5x MCRB ($25.4M).
- STOK has been more active in the news (7 items in the past 4 weeks vs 1 for MCRB).
- STOK has more recent analyst coverage (18 ratings vs 10 for MCRB).
- Company
- Seres Therapeutics Inc.
- Stoke Therapeutics Inc.
- Price
- $2.47-3.14%
- $24.20-1.71%
- Market cap
- $25.4M
- $1.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2019
- News (4w)
- 1
- 7
- Recent ratings
- 10
- 18
Seres Therapeutics Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Stoke Therapeutics Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Latest MCRB
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form EFFECT filed by Seres Therapeutics Inc.
- Officer Brady Kelly sold $291 worth of shares (64 units at $4.55) as part of a pre-agreed trading plan and converted options into 181 shares, increasing direct ownership by 1% to 8,679 units (SEC Form 4)
- Director Shaff Eric D. converted options into 722 shares and sold $1,197 worth of shares (263 units at $4.55) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 12,499 units (SEC Form 4)
- Officer Henn Matthew R converted options into 238 shares and sold $369 worth of shares (81 units at $4.55) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 7,995 units (SEC Form 4)
- Officer Desrosier Thomas sold $373 worth of shares (82 units at $4.55) as part of a pre-agreed trading plan and converted options into 245 shares, increasing direct ownership by 2% to 8,117 units (SEC Form 4)
- SEC Form S-3 filed by Seres Therapeutics Inc.
- SEC Form 10-Q filed by Seres Therapeutics Inc.
Latest STOK
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
- Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
- Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- GENERAL COUNSEL & CORP SEC Allan Jonathan sold $16,509 worth of shares (627 units at $26.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 20,598 units (SEC Form 4)
- CHIEF MEDICAL OFFICER Ticho Barry sold $27,494 worth of shares (1,051 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 19,059 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Stoke Therapeutics Inc.
- SEC Form 4 filed by Stoke Therapeutics Inc.
- SEC Form 3 filed by new insider Cumbo Alexander
- SEC Form 8-K filed by Stoke Therapeutics Inc.